P2RX7 and Crohn disease: Another P2X7 antagonist, AZD9056, has the therapeutic potential to decrease Crohn’s disease activity index along with improvement in chronic abdominal pain, as shown in a Phase 2a clinical study of Crohn’s disease (Table 1).